G1GLP1 Note Choose country

HomeGLP-1 Medicines Explained

GLP-1 Medicines Explained

Plain-language pages on each GLP-1 medicine: what it is, what it is approved for, doses and where to find its price. One page per medicine, including the ones still in trials.

All countries

Tirzepatide (Zepbound, Mounjaro) for Weight LossTirzepatide is a once-weekly injection sold as Zepbound and Mounjaro, with doses from 2.5 mg to 15 mg. There i

GLP-1 Drugs ExplainedGLP-1 drugs include semaglutide, tirzepatide and liraglutide injections and three daily pills. See each medici

Mounjaro (Tirzepatide)Mounjaro is a once-weekly tirzepatide injection approved for type 2 diabetes and, in the UK, EU and India, wei

Ozempic (Semaglutide)Ozempic is a once-weekly semaglutide injection for type 2 diabetes, 0.25 mg to 2 mg, not approved for weight l

Wegovy (Semaglutide) for Weight LossWegovy is Novo Nordisk's semaglutide for weight loss: a weekly injection (0.25 mg start, 2.4 mg usual, 7.2 mg

Semaglutide for Weight LossSemaglutide is the ingredient in Wegovy, Ozempic and Rybelsus. Wegovy is the weight-loss brand, as a weekly in

Wegovy PillThe Wegovy pill is once-daily semaglutide: 1.5 mg start, 25 mg maintenance from day 91. Doses, how to take it,

Foundayo (Orforglipron)Foundayo (orforglipron) is Lilly's once-daily GLP-1 weight loss pill. FDA approved April 1, 2026, UK August 10

Rybelsus (Semaglutide Tablets)Rybelsus is a once-daily semaglutide tablet for type 2 diabetes, not approved for weight loss. Tablet strength

Liraglutide (Saxenda, Victoza)Liraglutide is a once-daily injection. Saxenda is approved for weight loss and goes up to 3 mg; Victoza is for

Eloralintide and AmycretinEloralintide (Lilly) and amycretin (Novo Nordisk) are amylin weight loss drugs still in trials. Eloralintide c

Survodutide: Trial Results and Expected Approval TimelineSurvodutide is not approved anywhere as of November 20, 2026. In a 76-week phase 3 trial, weight fell about 12

CagriSema (Novo Nordisk)CagriSema is Novo Nordisk's once-weekly weight loss injection, not yet approved. FDA decision expected in Q4 2